Sacituzumab govitecan + Pembrolizumab
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Oct 10, 2024 → Sep 1, 2029
NCT ID
NCT06081244About Sacituzumab govitecan + Pembrolizumab
Sacituzumab govitecan + Pembrolizumab is a phase 3 stage product being developed by Merck for Triple Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06081244. Target conditions include Triple Negative Breast Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06081244 | Phase 3 | Recruiting |
| NCT05609968 | Phase 3 | Active |
| NCT04468061 | Phase 2 | Recruiting |
Competing Products
20 competing products in Triple Negative Breast Cancer